USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE
The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; slv |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | EKRE Hans-Peter WAHLGREN Mats LEITGEB Anna PIKAS Dagmar |
| description | The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SI2794666TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SI2794666TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SI2794666TT13</originalsourceid><addsrcrecordid>eNrjZHAODXZV8HdTcPZw9fV0dvTxiVTw9XfxdPN0dVHwcA1wDPL0U3BxDfIMcwxxDVYAcoI9nb19XBWcXX18FFw8g10dg115GFjTEnOKU3mhNDeDoptriLOHbmpBfnxqcUFicmpeakl8sKeRuaWJmZlZSIihMTFqAAPsK5w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE</title><source>esp@cenet</source><creator>EKRE Hans-Peter ; WAHLGREN Mats ; LEITGEB Anna ; PIKAS Dagmar</creator><creatorcontrib>EKRE Hans-Peter ; WAHLGREN Mats ; LEITGEB Anna ; PIKAS Dagmar</creatorcontrib><description>The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.</description><language>eng ; slv</language><subject>CHEMISTRY ; COMPOSITIONS BASED THEREON ; DERIVATIVES THEREOF ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC MACROMOLECULAR COMPOUNDS ; POLYSACCHARIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; THEIR PREPARATION OR CHEMICAL WORKING-UP</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180629&DB=EPODOC&CC=SI&NR=2794666T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180629&DB=EPODOC&CC=SI&NR=2794666T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>EKRE Hans-Peter</creatorcontrib><creatorcontrib>WAHLGREN Mats</creatorcontrib><creatorcontrib>LEITGEB Anna</creatorcontrib><creatorcontrib>PIKAS Dagmar</creatorcontrib><title>USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE</title><description>The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.</description><subject>CHEMISTRY</subject><subject>COMPOSITIONS BASED THEREON</subject><subject>DERIVATIVES THEREOF</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC MACROMOLECULAR COMPOUNDS</subject><subject>POLYSACCHARIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>THEIR PREPARATION OR CHEMICAL WORKING-UP</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHAODXZV8HdTcPZw9fV0dvTxiVTw9XfxdPN0dVHwcA1wDPL0U3BxDfIMcwxxDVYAcoI9nb19XBWcXX18FFw8g10dg115GFjTEnOKU3mhNDeDoptriLOHbmpBfnxqcUFicmpeakl8sKeRuaWJmZlZSIihMTFqAAPsK5w</recordid><startdate>20180629</startdate><enddate>20180629</enddate><creator>EKRE Hans-Peter</creator><creator>WAHLGREN Mats</creator><creator>LEITGEB Anna</creator><creator>PIKAS Dagmar</creator><scope>EVB</scope></search><sort><creationdate>20180629</creationdate><title>USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE</title><author>EKRE Hans-Peter ; WAHLGREN Mats ; LEITGEB Anna ; PIKAS Dagmar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SI2794666TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; slv</language><creationdate>2018</creationdate><topic>CHEMISTRY</topic><topic>COMPOSITIONS BASED THEREON</topic><topic>DERIVATIVES THEREOF</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC MACROMOLECULAR COMPOUNDS</topic><topic>POLYSACCHARIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>THEIR PREPARATION OR CHEMICAL WORKING-UP</topic><toplevel>online_resources</toplevel><creatorcontrib>EKRE Hans-Peter</creatorcontrib><creatorcontrib>WAHLGREN Mats</creatorcontrib><creatorcontrib>LEITGEB Anna</creatorcontrib><creatorcontrib>PIKAS Dagmar</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>EKRE Hans-Peter</au><au>WAHLGREN Mats</au><au>LEITGEB Anna</au><au>PIKAS Dagmar</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE</title><date>2018-06-29</date><risdate>2018</risdate><abstract>The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; slv |
| recordid | cdi_epo_espacenet_SI2794666TT1 |
| source | esp@cenet |
| subjects | CHEMISTRY COMPOSITIONS BASED THEREON DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC MACROMOLECULAR COMPOUNDS POLYSACCHARIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS THEIR PREPARATION OR CHEMICAL WORKING-UP |
| title | USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T02%3A27%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=EKRE%20Hans-Peter&rft.date=2018-06-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESI2794666TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |